Hadasit Bio-Holdings Ltd (HSITF) Stock
Hadasit Bio-Holdings Ltd, an Israeli biotechnology enterprise established in Jerusalem in 2005, focuses its efforts on critical therapeutic domains. These include oncology, regenerative medicine, and inflammatory diseases.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Hadasit Bio-Holdings Ltd
Hadasit Bio-Holdings Ltd, an Israeli biotechnology enterprise established in Jerusalem in 2005, focuses its efforts on critical therapeutic domains. These include oncology, regenerative medicine, and inflammatory diseases. A key offering is ProtAb, an immunotherapeutic monoclonal antibody engineered to treat autoimmune inflammatory disorders.
Hadasit Bio-Holdings Ltd is headquartered in IL.
Hadasit Bio-Holdings Ltd (HSITF) stock trades at $0.12 with a market capitalization of $1.33M. The stock is valued at a price-to-earnings (P/E) ratio of -4.57, price-to-book of 6.18, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.12 and $0.13, and currently trades 7.7% below its 52-week high.
On profitability, Hadasit Bio-Holdings Ltd generates a return on equity (ROE) of -135.23%, return on capital employed of -71.58%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.hbl.co.il